Mereo BioPharma Group plc
MREO
$2.17
-$0.08-3.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.00% | -50.00% | -- | -- | -88.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.00% | -50.00% | -- | -- | -88.89% |
| Cost of Revenue | 148.35% | 125.98% | -- | -- | -110.98% |
| Gross Profit | -71.09% | -75.60% | -- | -- | -80.45% |
| SG&A Expenses | 7.17% | 10.16% | 55.46% | 43.46% | 4.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.34% | 15.97% | 32.71% | 23.10% | -7.64% |
| Operating Income | -19.11% | -17.71% | -84.45% | -68.46% | -14.32% |
| Income Before Tax | 9.32% | -32.56% | -75.59% | -44.18% | -53.63% |
| Income Tax Expenses | -- | -- | -- | -- | -734.84% |
| Earnings from Continuing Operations | 8.26% | -34.48% | -79.14% | -46.78% | -51.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.26% | -34.48% | -79.14% | -46.78% | -51.43% |
| EBIT | -19.11% | -17.71% | -84.45% | -68.46% | -14.32% |
| EBITDA | -19.63% | -17.96% | -86.64% | -69.86% | -14.07% |
| EPS Basic | 15.84% | -20.43% | -63.27% | -31.05% | -32.81% |
| Normalized Basic EPS | 16.34% | -18.67% | -60.00% | -28.78% | -34.86% |
| EPS Diluted | 15.84% | -20.43% | -63.27% | -31.05% | -28.50% |
| Normalized Diluted EPS | 16.34% | -18.67% | -60.00% | -28.78% | -34.86% |
| Average Basic Shares Outstanding | 9.60% | 11.87% | 12.08% | 12.14% | 12.59% |
| Average Diluted Shares Outstanding | 9.60% | 11.87% | 12.08% | 12.14% | 12.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |